Differential regulation of striatal G protein levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in C57 BL/6 mice

Neuroscience Letters

Volumn 306, Issue 1-2, 2001, Pages 21-24

  Marcotte, Eric R ^a   Chugh, Anita ^a   Barlas, Cia ^a   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine; G protein; Parkinson's disease; Supersensitivity

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; BRAIN PROTEIN; DOPAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN;

ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CATECHOLAMINE BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DOPAMINE AGENTS; DOWN-REGULATION; GTP-BINDING PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEURONS; PARKINSONIAN DISORDERS; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 0035933667     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(01)01848-1     Document Type: Article

References (23)

1. Regulations of dopamine receptor subunit D1 and neuropeptide substance P in the primate basal ganglia following nigrostriatal dopamine denervation
2. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on striatal dopamine receptors in C57BL/6 mice
3. 2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: Lack of evidence of receptor modifications in parkinsonian mice
4. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys
5. Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography
6. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
7. The pathophysiological basis of Parkinson's disease
8. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
9. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse
10. 35S]GTPγS binding in rat and monkey brain
11. 1 receptor with adenylyl cyclase
12. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system
13. G proteins and animal models of Parkinson's disease
14. Striatal G-proteins: Effects of unilateral 6-hydroxydopamine lesions
15. MPTP-induced parkinsonian model in mice: Biochemistry, pharmacology and behaviour
16. 2 receptor hypersensitivity in the mouse is transient
17. Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease
18. Developmental changes in Gs and Golf proteins and adenylyl cyclases in mouse brain membranes
19. Dopamine receptors and transporters in Parkinson's disease and schizophrenia
20. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1)
21. Dopamine receptor gene expression: Effects of neuroleptics, denervation, and development
22. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
23. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons